Design Therapeutics (DSGN) Accounts Payables (2020 - 2026)

Design Therapeutics' Accounts Payables history runs 7 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• In Q1 2026, Accounts Payables fell 54.98% year-over-year to $2.3 million; the TTM figure through Mar 2026 stood at $2.3 million (down 54.98% YoY), while the FY2025 annual figure was $10.7 million, up 391.45% from the prior year.
• Accounts Payables came in at $2.3 million for Q1 2026 at Design Therapeutics, down from $10.7 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $10.7 million in Q4 2025 to a low of $1.0 million in Q2 2025.
• A 5-year average of $4.7 million and a median of $5.1 million in 2025 frame the typical range for Accounts Payables.
• Across the five-year window, Accounts Payables surged 393.05% in 2023 and tumbled 80.13% in 2025, its largest moves.
• Design Therapeutics' Accounts Payables stood at $7.8 million in 2022, then plunged by 74.97% to $1.9 million in 2023, then rose by 12.68% to $2.2 million in 2024, then jumped by 391.45% to $10.7 million in 2025, then sank by 78.81% to $2.3 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $2.3 million, $10.7 million, and $1.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison